TWI851729B - 經取代1-氧代-異吲哚啉-5-羧醯胺化合物，其組成物，及以此治療之方法 - Google Patents

經取代1-氧代-異吲哚啉-5-羧醯胺化合物，其組成物，及以此治療之方法 Download PDF

Info

Publication number
TWI851729B
TWI851729B TW109117973A TW109117973A TWI851729B TW I851729 B TWI851729 B TW I851729B TW 109117973 A TW109117973 A TW 109117973A TW 109117973 A TW109117973 A TW 109117973A TW I851729 B TWI851729 B TW I851729B
Authority
TW
Taiwan
Prior art keywords
dioxopiperidin
carboxamide
oxo
trifluoro
ethyl
Prior art date
Application number
TW109117973A
Other languages
English (en)
Chinese (zh)
Other versions
TW202110819A (zh
Inventor
法蘭斯 巴庫里
凱薩琳 諾斯克特
馬修 D 寇瑞亞
約書亞 漢森
羅莉 Ａ 勒布倫
盧錦淳
剛 盧
馬克 Ａ 納吉
曉暉 彭
寧科維奇 蘇菲 佩林
Original Assignee
美商西建公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商西建公司 filed Critical 美商西建公司
Publication of TW202110819A publication Critical patent/TW202110819A/zh
Application granted granted Critical
Publication of TWI851729B publication Critical patent/TWI851729B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
TW109117973A 2019-05-31 2020-05-29 經取代1-氧代-異吲哚啉-5-羧醯胺化合物，其組成物，及以此治療之方法 TWI851729B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962855619P 2019-05-31 2019-05-31
US62/855,619 2019-05-31

Publications (2)

Publication Number Publication Date
TW202110819A TW202110819A (zh) 2021-03-16
TWI851729B true TWI851729B (zh) 2024-08-11

Family

ID=73551319

Family Applications (2)

Application Number Title Priority Date Filing Date
TW109117973A TWI851729B (zh) 2019-05-31 2020-05-29 經取代1-氧代-異吲哚啉-5-羧醯胺化合物，其組成物，及以此治療之方法
TW113131211A TW202523657A (zh) 2019-05-31 2020-05-29 經取代1-氧代-異吲哚啉-5-羧醯胺化合物，其組成物，及以此治療之方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW113131211A TW202523657A (zh) 2019-05-31 2020-05-29 經取代1-氧代-異吲哚啉-5-羧醯胺化合物，其組成物，及以此治療之方法

Country Status (19)

Country Link
US (2) US11306101B2 (enExample)
EP (1) EP3976595A4 (enExample)
JP (2) JP7496838B2 (enExample)
KR (2) KR102913106B1 (enExample)
CN (4) CN114957212B (enExample)
AR (1) AR119057A1 (enExample)
AU (1) AU2020282748A1 (enExample)
BR (1) BR112021022758A2 (enExample)
CA (1) CA3136753A1 (enExample)
CL (1) CL2021003134A1 (enExample)
CO (1) CO2021015624A2 (enExample)
IL (1) IL288278B2 (enExample)
MX (1) MX2021014350A (enExample)
MY (1) MY208545A (enExample)
PE (1) PE20220569A1 (enExample)
SG (1) SG11202112872YA (enExample)
TW (2) TWI851729B (enExample)
WO (1) WO2020243379A1 (enExample)
ZA (1) ZA202109003B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102913106B1 (ko) 2019-05-31 2026-01-19 셀진 코포레이션 치환된 1-옥소-이소인돌린-5-카르복스아미드 화합물, 그의 조성물 및 그를 사용한 치료 방법
MX2023004374A (es) * 2020-10-14 2023-07-06 C4 Therapeutics Inc Ligandos tricíclicos para la degradación de la familia ikaros 2 o la familia ikaros 4.
CN112679421A (zh) * 2021-01-04 2021-04-20 都创(上海)医药科技股份有限公司 一种(r)-3-氯吡啶基-2-三氟乙胺盐酸盐的合成方法
AU2022207648A1 (en) 2021-01-13 2023-07-27 Monte Rosa Therapeutics Ag Isoindolinone compounds
CN118019534A (zh) * 2021-05-06 2024-05-10 细胞基因公司 使用n-((r)-1-(3-氯吡啶-2-基)-2,2,2-三氟乙基)-2-((s)-2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-甲酰胺的治疗方法
CA3221549A1 (en) * 2021-06-08 2022-12-15 Liqiang Fu Isoindolinone compounds, and uses thereof
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
US12122764B2 (en) 2021-12-22 2024-10-22 Gilead Sciences, Inc. IKAROS zinc finger family degraders and uses thereof
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
EP4540240A1 (en) * 2022-06-16 2025-04-23 Monte Rosa Therapeutics AG Molecular glue degraders and methods of using the same
EP4540238A1 (en) * 2022-06-16 2025-04-23 Monte Rosa Therapeutics AG Molecular glue degraders and methods of using the same
WO2024027694A1 (zh) * 2022-08-01 2024-02-08 苏州开拓药业股份有限公司 一种蛋白降解剂
JP2025541841A (ja) * 2022-12-07 2025-12-23 ハンジョウ グルバイオ ファーマシューティカル カンパニー リミテッド オキソイソインドール－５－カルボキサミド系化合物またはその塩、溶媒和物の結晶形または無定形
JP2025541840A (ja) * 2022-12-07 2025-12-23 ハンジョウ グルバイオ ファーマシューティカル カンパニー リミテッド 固体分散体、その製造方法と使用
PL249026B1 (pl) * 2022-12-09 2026-02-23 Univ Mikolaja Kopernika W Toruniu Pochodna azetydyno-2,4-dionu, sposób jej otrzymywania i zastosowanie

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150005303A1 (en) * 2006-08-30 2015-01-01 Celgene Corporation 5-substituted isoindoline compounds
US20180134684A1 (en) * 2015-07-07 2018-05-17 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
UA91560C2 (ru) 2005-08-31 2010-08-10 Селджин Корпорэйшн Соединения ряда изоиндолимидов, их композиция и применение
CL2007002513A1 (es) 2006-08-30 2008-04-04 Celgene Corp Soc Organizada Ba Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
ZA200901078B (en) * 2006-08-30 2010-06-30 Celgene Corp 5-substituted isoindoline compounds
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
WO2017024318A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
WO2017024317A2 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
KR102913106B1 (ko) 2019-05-31 2026-01-19 셀진 코포레이션 치환된 1-옥소-이소인돌린-5-카르복스아미드 화합물, 그의 조성물 및 그를 사용한 치료 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150005303A1 (en) * 2006-08-30 2015-01-01 Celgene Corporation 5-substituted isoindoline compounds
US20180134684A1 (en) * 2015-07-07 2018-05-17 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules

Also Published As

Publication number Publication date
KR20220016167A (ko) 2022-02-08
PE20220569A1 (es) 2022-04-20
US12486281B2 (en) 2025-12-02
US11306101B2 (en) 2022-04-19
AU2020282748A1 (en) 2021-12-09
CN114269729B (zh) 2025-01-17
CN114957212B (zh) 2024-05-24
US20200377512A1 (en) 2020-12-03
CN114957212A (zh) 2022-08-30
JP2022534979A (ja) 2022-08-04
KR20250078628A (ko) 2025-06-02
IL288278B1 (en) 2025-05-01
CL2021003134A1 (es) 2022-07-01
AR119057A1 (es) 2021-11-17
CA3136753A1 (en) 2020-12-03
TW202110819A (zh) 2021-03-16
CN119930578A (zh) 2025-05-06
CN118724867A (zh) 2024-10-01
WO2020243379A1 (en) 2020-12-03
ZA202109003B (en) 2025-01-29
MY208545A (en) 2025-05-14
KR102913106B1 (ko) 2026-01-19
IL288278B2 (en) 2025-09-01
EP3976595A4 (en) 2023-01-04
TW202523657A (zh) 2025-06-16
CO2021015624A2 (es) 2022-02-28
SG11202112872YA (en) 2021-12-30
IL288278A (en) 2022-01-01
EP3976595A1 (en) 2022-04-06
JP2024123001A (ja) 2024-09-10
CN114269729A (zh) 2022-04-01
JP7496838B2 (ja) 2024-06-07
BR112021022758A2 (pt) 2022-03-22
US20220213115A1 (en) 2022-07-07
MX2021014350A (es) 2022-02-21

Similar Documents

Publication Publication Date Title
TWI851729B (zh) 經取代1-氧代-異吲哚啉-5-羧醯胺化合物，其組成物，及以此治療之方法
EP3897636B1 (en) Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
KR102783925B1 (ko) 치환된 4-아미노이소인돌린-1,3-디온 화합물 및 림프종의 치료를 위한 이의 용도
TW202341983A (zh) 用於降解突變kras蛋白之化合物及其應用
US20260098028A1 (en) Compounds and Their Use for Treatment of Hemoglobinopathies
CN119585256A (zh) 趋化因子受体调节剂及其用途
CN109563095B (zh) 动物和人抗疟剂
JP2026505349A (ja) 改変されたタンパク質の選択的分解のための化合物および組成物
EA050422B1 (ru) Замещенные 1-оксоизоиндолин-5-карбоксамидные соединения, содержащие их композиции и способы лечения с их помощью
EA046753B1 (ru) Замещенные 1-оксоизоиндолин-5-карбоксамидные соединения, содержащие их композиции и способы лечения с их помощью
US20250368620A1 (en) ARNT Degrading Compounds and Uses Thereof
TW202606669A (zh) Ａｒｎｔ降解化合物及其用途